Influence of indinavir on virulence and growth of Cryptococcus neoformans

Journal of Infectious Diseases

Volumn 191, Issue 2, 2005, Pages 307-311

  Monari, Claudia ^a   Pericolini, Eva ^a   Bistoni, Giovanni ^b   Cenci, Elio ^a   Bistoni, Francesco ^a   Vecchiarelli, Anna ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; MELANIN; PHOSPHOLIPASE; PROTEINASE; UREASE;

ARTICLE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG CAPSULE; EFFECTOR CELL; FUNGUS GROWTH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; VIRULENCE;

CELL CULTURE TECHNIQUES; CRYPTOCOCCUS NEOFORMANS; HIV PROTEASE INHIBITORS; INDINAVIR; VIRULENCE;

EID: 11844285691     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/426828     Document Type: Article

References (15)

1. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
2. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999; 180:448-53.
3. Manfredi R, Calza L, Chiodo F. AIDS-associated Cryptococcus infection before and after the highly active antiretroviral therapy era: emerging management problems. Int J Antimicrob Agents 2003; 22:449-52.
4. Bobin S, Bouhouere D, Dumpt S, Boibieux A, Grault A, Peyrnamond D. Importance of antiprotease in the treatment of microsporidia and/ or cryptosporidia infections in HIV-seropositive patients. Pathol Biol 1998; 46:418-9.
5. Retini C, Casadevall A, Pietrella D, Monari C, Palazzetti B, Vecchiarelli A. Specific activated T cells regulate IL-12 production by human monocytes stimulated with Cryptococcus neoformans. J Immunol 1999; 162:1618-23.
6. Polak A. Virulence of Candida albicans mutants. Mycoses 1992; 35:9-16.
7. Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia 1982; 20:7-14.
8. Franzot SP, Mukherjee J, Cherniak R, Chen LC, Hamdan JS, Casadevall A. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun 1998; 66:89-97.
9. Monari C, Casadevall A, Retini C, Baldelli F, Bistoni F, Vecchiarelli A. Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans. AIDS 1999; 13:653-60.
10. Vecchiarelli A, Pietrella D, Dottorini M, Monari C, Retini C, Todisco T. Encapsulation of Cryptococcus neoformans regulates fungicidal activity. Exp Immunol 1994; 98:217-23.
11. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338:1281-92.
12. Rodrigues ML, dos Reis FCG, Puccia R, Travassos LR, Alviano CS. Cleavage of human fibronectin and other basement membrane-associated proteins by Cryptococcus neoformans serine proteinase. Microb Pathog 2003; 34:65-71.
13. Gary MC, Mukherjee J, Cole GT, Casadevall A, Perfect JR. Urease as a virulence factor in experimental cryptococcisis. Infect Immun 2000; 68:443-8.
14. Klebanoff SJ. Myeloperoxidase: contribution to the microbicidal activity of intact leukocytes. Science 1970; 169:1095-97.
15. Vecchiarelli A. Immunoregulation by capsular components of Cryptococcus neoformans. Med Mycol 2000; 38:407-17.